Erratum: Ofatumumab, a novel CD20 monoclonal antibody, is active in patients with fludarabine- and alemtuzumab-refractory or bulky fludarabine-refractory chronic lymphocytic leukemia irrespective of prior rituximab (Clinical lymphoma & Myeloma (2009) 9: 6 (E36) DOI: 10.3816/CLM.2009.n.098)

William Wierda; Thomas Kipps; Jiří Mayer; Stephan Stilgenbauer; Cathy D. Williams; Andrzej Hellmann; Tadeusz Robak; Richard R. Furman; Peter Hillmen; Marek Trneny; Martin J.S. Dyer; Swami Padmanabhan; Magdalena Piotrowska; Tomas Kozak; Geoffrey Chan; Randy Davis; Nedjad Losic; Joris Wilms; Charlotte Russell; Anders Österborg

doi:10.3816/CLML.2010.n.024

Erratum: Ofatumumab, a novel CD20 monoclonal antibody, is active in patients with fludarabine- and alemtuzumab-refractory or bulky fludarabine-refractory chronic lymphocytic leukemia irrespective of prior rituximab (Clinical lymphoma & Myeloma (2009) 9: 6 (E36) DOI: 10.3816/CLM.2009.n.098)

William Wierda, Thomas Kipps, Jiří Mayer, Stephan Stilgenbauer, Cathy D. Williams, Andrzej Hellmann, Tadeusz Robak, Richard R. Furman, Peter Hillmen, Marek Trneny, Martin J.S. Dyer, Swami Padmanabhan, Magdalena Piotrowska, Tomas Kozak, Geoffrey Chan, Randy Davis, Nedjad Losic, Joris Wilms, Charlotte Russell, Anders Österborg

Academic Institute

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	157
Number of pages	1
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	10
Issue number	2
DOIs	https://doi.org/10.3816/CLML.2010.n.024
State	Published - Apr 2010

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.3816/CLML.2010.n.024

Cite this

Wierda, W., Kipps, T., Mayer, J., Stilgenbauer, S., Williams, C. D., Hellmann, A., Robak, T., Furman, R. R., Hillmen, P., Trneny, M., Dyer, M. J. S., Padmanabhan, S., Piotrowska, M., Kozak, T., Chan, G., Davis, R., Losic, N., Wilms, J., Russell, C., & Österborg, A. (2010). Erratum: Ofatumumab, a novel CD20 monoclonal antibody, is active in patients with fludarabine- and alemtuzumab-refractory or bulky fludarabine-refractory chronic lymphocytic leukemia irrespective of prior rituximab (Clinical lymphoma & Myeloma (2009) 9: 6 (E36) DOI: 10.3816/CLM.2009.n.098). Clinical Lymphoma, Myeloma and Leukemia, 10(2), 157. https://doi.org/10.3816/CLML.2010.n.024

Erratum : Ofatumumab, a novel CD20 monoclonal antibody, is active in patients with fludarabine- and alemtuzumab-refractory or bulky fludarabine-refractory chronic lymphocytic leukemia irrespective of prior rituximab (Clinical lymphoma & Myeloma (2009) 9: 6 (E36) DOI: 10.3816/CLM.2009.n.098). / Wierda, William; Kipps, Thomas; Mayer, Jiří; Stilgenbauer, Stephan; Williams, Cathy D.; Hellmann, Andrzej; Robak, Tadeusz; Furman, Richard R.; Hillmen, Peter; Trneny, Marek; Dyer, Martin J.S.; Padmanabhan, Swami; Piotrowska, Magdalena; Kozak, Tomas; Chan, Geoffrey; Davis, Randy; Losic, Nedjad; Wilms, Joris; Russell, Charlotte; Österborg, Anders.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 10, No. 2, 04.2010, p. 157.

Research output: Contribution to journal › Comment/debate › peer-review

Wierda, W, Kipps, T, Mayer, J, Stilgenbauer, S, Williams, CD, Hellmann, A, Robak, T, Furman, RR, Hillmen, P, Trneny, M, Dyer, MJS, Padmanabhan, S, Piotrowska, M, Kozak, T, Chan, G, Davis, R, Losic, N, Wilms, J, Russell, C & Österborg, A 2010, 'Erratum: Ofatumumab, a novel CD20 monoclonal antibody, is active in patients with fludarabine- and alemtuzumab-refractory or bulky fludarabine-refractory chronic lymphocytic leukemia irrespective of prior rituximab (Clinical lymphoma & Myeloma (2009) 9: 6 (E36) DOI: 10.3816/CLM.2009.n.098)', Clinical Lymphoma, Myeloma and Leukemia, vol. 10, no. 2, pp. 157. https://doi.org/10.3816/CLML.2010.n.024

Wierda W, Kipps T, Mayer J, Stilgenbauer S, Williams CD, Hellmann A et al. Erratum: Ofatumumab, a novel CD20 monoclonal antibody, is active in patients with fludarabine- and alemtuzumab-refractory or bulky fludarabine-refractory chronic lymphocytic leukemia irrespective of prior rituximab (Clinical lymphoma & Myeloma (2009) 9: 6 (E36) DOI: 10.3816/CLM.2009.n.098). Clinical Lymphoma, Myeloma and Leukemia. 2010 Apr;10(2):157. https://doi.org/10.3816/CLML.2010.n.024

Wierda, William ; Kipps, Thomas ; Mayer, Jiří ; Stilgenbauer, Stephan ; Williams, Cathy D. ; Hellmann, Andrzej ; Robak, Tadeusz ; Furman, Richard R. ; Hillmen, Peter ; Trneny, Marek ; Dyer, Martin J.S. ; Padmanabhan, Swami ; Piotrowska, Magdalena ; Kozak, Tomas ; Chan, Geoffrey ; Davis, Randy ; Losic, Nedjad ; Wilms, Joris ; Russell, Charlotte ; Österborg, Anders. / Erratum : Ofatumumab, a novel CD20 monoclonal antibody, is active in patients with fludarabine- and alemtuzumab-refractory or bulky fludarabine-refractory chronic lymphocytic leukemia irrespective of prior rituximab (Clinical lymphoma & Myeloma (2009) 9: 6 (E36) DOI: 10.3816/CLM.2009.n.098). In: Clinical Lymphoma, Myeloma and Leukemia. 2010 ; Vol. 10, No. 2. pp. 157.

@article{11174b07595a4f18abcdb78973f2f3f9,

title = "Erratum: Ofatumumab, a novel CD20 monoclonal antibody, is active in patients with fludarabine- and alemtuzumab-refractory or bulky fludarabine-refractory chronic lymphocytic leukemia irrespective of prior rituximab (Clinical lymphoma & Myeloma (2009) 9: 6 (E36) DOI: 10.3816/CLM.2009.n.098)",

author = "William Wierda and Thomas Kipps and Ji{\v r}{\'i} Mayer and Stephan Stilgenbauer and Williams, {Cathy D.} and Andrzej Hellmann and Tadeusz Robak and Furman, {Richard R.} and Peter Hillmen and Marek Trneny and Dyer, {Martin J.S.} and Swami Padmanabhan and Magdalena Piotrowska and Tomas Kozak and Geoffrey Chan and Randy Davis and Nedjad Losic and Joris Wilms and Charlotte Russell and Anders {\"O}sterborg",

year = "2010",

month = apr,

doi = "10.3816/CLML.2010.n.024",

language = "English (US)",

volume = "10",

pages = "157",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Cancer Media Group",

number = "2",

}

TY - JOUR

T1 - Erratum

T2 - Ofatumumab, a novel CD20 monoclonal antibody, is active in patients with fludarabine- and alemtuzumab-refractory or bulky fludarabine-refractory chronic lymphocytic leukemia irrespective of prior rituximab (Clinical lymphoma & Myeloma (2009) 9: 6 (E36) DOI: 10.3816/CLM.2009.n.098)

AU - Wierda, William

AU - Kipps, Thomas

AU - Mayer, Jiří

AU - Stilgenbauer, Stephan

AU - Williams, Cathy D.

AU - Hellmann, Andrzej

AU - Robak, Tadeusz

AU - Furman, Richard R.

AU - Hillmen, Peter

AU - Trneny, Marek

AU - Dyer, Martin J.S.

AU - Padmanabhan, Swami

AU - Piotrowska, Magdalena

AU - Kozak, Tomas

AU - Chan, Geoffrey

AU - Davis, Randy

AU - Losic, Nedjad

AU - Wilms, Joris

AU - Russell, Charlotte

AU - Österborg, Anders

PY - 2010/4

Y1 - 2010/4

UR - http://www.scopus.com/inward/record.url?scp=84860605156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860605156&partnerID=8YFLogxK

U2 - 10.3816/CLML.2010.n.024

DO - 10.3816/CLML.2010.n.024

M3 - Comment/debate

AN - SCOPUS:84860605156

VL - 10

SP - 157

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2650

IS - 2

ER -

Erratum: Ofatumumab, a novel CD20 monoclonal antibody, is active in patients with fludarabine- and alemtuzumab-refractory or bulky fludarabine-refractory chronic lymphocytic leukemia irrespective of prior rituximab (Clinical lymphoma & Myeloma (2009) 9: 6 (E36) DOI: 10.3816/CLM.2009.n.098)

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this